Trial Profile
A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Feb 2015
Price :
$35
*
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker
- Sponsors CuraGen Corporation
- 06 Jun 2010 Primary endpoint 'Progression free survival rate' has been met in the phase II portion of the trial, according to a Celldex Therapeutics media release.
- 06 Jun 2010 Results were presented at the 46th Annual Meeting of ASCO, according to a Celldex Therapeutics media release.
- 14 Dec 2009 Status changed from active, no longer recruiting to completed, according to a Celldex Therapeutics media release.